Free Trial
NASDAQ:SLGL

Sol-Gel Technologies Q1 2025 Earnings Report

Sol-Gel Technologies logo
$22.67 -3.13 (-12.13%)
Closing price 04:00 PM Eastern
Extended Trading
$22.20 -0.47 (-2.07%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies EPS Results

Actual EPS
-$3.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 23, 2025
Conference Call Time
7:00AM ET

Earnings Documents

Sol-Gel Technologies Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
Sol-Gel Technologies Reports Strong Q2 2025 Results
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

View Sol-Gel Technologies Profile

More Earnings Resources from MarketBeat